NCT01696435View on ClinicalTrials.gov

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

NAActive, not recruitingINTERVENTIONAL
Enrollment

18,353

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2021

Study Completion Date

April 30, 2025

Conditions
DepressionDepressive SymptomsMood
Interventions
DIETARY_SUPPLEMENT

vitamin D3

Vitamin D3 (cholecalciferol), 2000 IU per day

DRUG

omega-3 fatty acids (fish oil)

Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

DIETARY_SUPPLEMENT

Fish oil placebo

Fish oil placebo

DIETARY_SUPPLEMENT

Vitamin D placebo

Vitamin D placebo

Trial Locations (1)

02215

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT01696435 - VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL | Biotech Hunter | Biotech Hunter